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Abstract. Positron emission tomography (PET) allows, in 
combination with multiple radiopharmaceuticals, unique 
physiological and biochemical tissue characterization. 
Tracers of blood flow, metabolism and neuronal function 
have been employed with this technique for research ap- 
plication. More recently, PET has emerged in cardiology 
as a useful tool for the detection of coronary artery dis- 
ease and the evaluation of tissue viability. Metabolic trac- 
ers such as fluorine-18 deoxyglucose (FDG) permit the 
specific delineation of ischaemically compromised myo- 
cardium. Clinical studies have indicated that the 
metabolic imaging is helpful in selecting patients for 
coronary artery bypass surgery or coronary angioplasty. 
More recent research work has concentrated on the use 
of carbon-11 acetate as a marker of myocardial oxygen 
consumption. Together with measurements of left ven- 
tricular performance, estimates of cardiac efficiency can 
be derived from dynamic HC-acetate studies. The non-in- 
vasive evaluation of the autonomic nervous system of the 
heart was limited in the past. With the introduction of 
radiopharmaceuticals which specifically bind to neuronal 
structures, the regional integrity of the autonomic ner- 
vous system of the heart can be evaluated with PET. Nu- 
merous tracers for pre- and postsynaptic binding sites 
have been synthesized, llC-hydroxyephedrine represents 
a new catecholamine analogue which is stored in cardiac 
presynaptic sympathetic nerve terminals. Initial clinical 
studies with it suggest a promising role for PET in the 
study of the sympathetic nervous system in various car- 
diac diseases such as cardiomyopathy, ischaemic heart 
disease and diabetes mellitus. The specificity of the radio- 
pharmaceuticals and the quantitative measurements of 
tissue tracer distribution provided by PET make this 
technology a very attractive research tool in the cardio- 
vascular sciences with great promise in the area of car- 
diac metabolism and neurocardiology. 
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I n t r o d u c t i o n  
Cardiac imaging has developed rapidly over the past 
20 years. Scintigraphic techniques excel in the evaluation 
of blood flow and left ventricular function. With the 
introduction of positron emission tomography (PET), 
numerous physiological and biochemical tissue functions 
can be assessed with specific radiopharmaceuticals trac- 
ing metabolism or neuronal function. 
The contractile and electrophysiological properties of 
the heart are dependent on the underlying cellular me- 
tabolism. Measurements of substrate utilization by the 
heart were first possible after the introduction of coro- 
nary sinus catheterization by Bing in 1947 (Bing 1954). 
This invasive technique, relying on the measurement of 
the arteriovenous differences of substrate concentra- 
tions, was used to assess the metabolism of the heart 
globally. However, regional differences in cardiac metab- 
olism are expected in ischaemic heart disease, which can- 
not be assessed by metabolic measurements based on 
arteriovenous sampling. With the recent introduction of 
metabolic tracer techniques in combination with single 
photon emission tomography (SPET) and PET, the non- 
invasive assessment of the regional biochemistry of the 
heart has become possible. Similarly, radiopharmaceuti- 
cals tracing the sympathetic and parasympathetic ner- 
vous system have been synthesized which allow us, for 
the first time, to non-invasively evaluate the regional 
integrity of cardiac innervation. 
This review will focus on PET technology and its 
application for the study of cardiac metabolism and au- 
tonomic nervous function. The clinical application of 
this technique as well as its use as a sophisticated re- 
search tool will be discussed. 
Among human organs, the heart has one of the high- 
est energy demands per gram of tissue: The oxygen re- 
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Fig. l. Substrates contributing to the myocardial energy metabo- 
lism. Acetyl-coenzyme A (CoA) represents the final product of 
various pathways entering the tricarboxylic acid cycle and provides 
ATP generation 
quirements of the heart average 6-8 ml per minute per 
100 g at rest compared with only 0.15 ml per min per 
100 g for resting skeletal muscle. Approximately 80% 
of the myocardial oxygen consumption is related to me- 
chanical work, with only 20% used to maintain cellular 
integrity. In line with this high energy demand, the ex- 
traction of oxygen by myocardial tissue is high and can 
only be slightly increased in response to an increased 
oxygen demand. Therefore, the myocardial blood flow 
must be closely matched to the energy demand in the 
normal heart. The heart displays a remarkable ability 
to metabolize a large variety of energy-providing sub- 
strates. Depending on the plasma substrate level, hor- 
monal factors, and myocardial oxygen supply and de- 
mand, the heart preferentially selects free fatty acids, 
glucose, lactate, pyruvate, ketone bodies or amino acids 
(Bing 1965; Liedtke 1981 ; Neely and Morgan 1974; Opie 
et al. 1975). Under fasting conditions, the normal heart 
produces as much as 70% of its energy by free fatty 
acid oxidation (Bing 1965; Neely and Morgan 1974). 
Glucose oxidation accounts for the remaining 30% of 
energy production. Following carbohydrate loading, 
plasma insulin and glucose levels increase while the free 
fatty acid levels decrease. Under these circumstances, 
the heart primarily metabolizes glucose. During exercise, 
lactate production provides an important alternate ener- 
gy source for cardiac metabolism (Liedtke 1981). In the 
myocyte, each energy-providing substrate enters its spe- 
cific metabolic pathway and finally contributes to acetyl- 
coenzyme A (CoA) production (Fig. 1). Acetyl-CoA 
then enters the tricarboxylic acid cycle. High energy 
phosphates, or ATP, represent the final product of sub- 
strate metabolism, and their subsequent hydrolysis 
maintains cardiac performance. During ischaemia, beta- 
oxidation of free fatty acids, which is very sensitive to 
the oxygen supply, is rapidly impaired (Liedtke 1981; 
Opie et al. 1975). The production of energy during 
ischaemia depends principally on accelerated glycogen 
breakdown and increased glycolytic flux (Liedtke 1981). 
However, in very low flow ischaemia, glycolysis may 
cease through the accumulation of metabolites such as 
lactate, produced by the non-oxidative utilization of glu- 
cose (Opie et al. 1975). As high energy phosphate pro- 
duction primarily depends on aerobic cellular metabo- 
lism, a decrease of the oxygen supply leads to insufficient 
ATP synthesis to maintain myocyte contraction. The 
transient energy supply by anaerobic metabolism during 
ischaemia may, however, be beneficial for preserving the 
integrity of the cell membrane and, hence, cell survival. 
Positron emission tomography 
PET relies on the detection of a coincidence of photons 
from positron annihilation using aligned detectors. By 
the association of multiple paired detectors, most state- 
of-the-art tomographs currently allow the simultaneous 
definition of the tracer spatial distribution of the entire 
heart. Image correction for tissue attenuation allows for 
regional quantification of the tracer distribution. The 
current spatial resolution provided by PET (range be- 
tween 5 and 10 mm) does not compete with that for 
echocardiography and magnetic resonance spectro- 
scopy. However, PET excells by its sensitivity which al- 
lows the detection of low tissue concentrations of radio- 
activity. This ability minimizes the patient's exposure 
to radiation and the pharmacological effects of most 
of the radiopharmaceuticals. The commonly used posi- 
tron emitters include oxygen-15, carbon-11, nitrogen-13 
and fluorine-18, which can be implemented in a variety 
of biologically active compounds without affecting their 
physiological behaviour. Thus, PET benefits from a vir- 
tually unlimited number of tracers to explore specific 
myocardial functions. Furthermore, the short half-lives 
of positron emitters allow rapid sequential studies of 
cardiac metabolism in response to changing workload 
conditions, substrate availability or oxygen supply; how- 
ever, this also demands the presence of an on-site cyclo- 
tron for their production and sophisticated radiochemi- 
cal technologies for their incorporation into the sub- 
strate. 
Metabolic PET tracers 
The development of metabolic tracers concentrated ini- 
tially on fatty acids and glucose metabolism (Fig. 2). 
The most widely employed radiopharmaceuticals are 
11C_palmitate, 11C-acetate and 1SF-deoxyglucose, which 
will be discussed. 
The fatty acid ~iC-palmitate has been introduced to 
characterize the metabolism of fatty acids in the myocar- 
dium (Bergmann 1989; Schelbert et al. 1983 a, b; Sch6n 
et al. 1982; Sobel et al. 1977). Avidly extracted by the 
myocardium, the initial uptake of ~ ~C-palmitate primar- 
ily represents blood flow. The ~lC-palmitate activity 
then clears from the myocardium according to a biex- 
ponential pattern. The early rapid clearance phase re- 
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Fig. 2. Metabolic pathways of myocardial substrate metabolism: 
carbon-ll palmitate and fluorine-18 fluorodeoxyglucose (lSF- 
FDG) trace the metabolic fate of free fatty acids and glucose, 
respectively. 11C-acetate enters the tricarboxylic acid cycle (TCA) 
and gives an estimation of the cardiac oxidative metabolism inde- 
pendent of overall substrate utilization. TG, triglycerides; FA, fatty 
acids 
flects the fatty acid beta-oxidation, while the slow clear- 
ance represents incorporation of the tracer in the lipid 
pool (Sch6n et al. 1982). Under different experimental 
conditions, the size and the rate of the early clearance 
correlated well with changes in cardiac workload and 
substrate utilization (Schelbert et al. 1983 b). 11C_palmi_ 
tare PET studies have contributed to a better under- 
standing of fatty acid metabolism. However, the contam- 
ination of the early clearance phase by back-diffusion 
of unmetabolized tracer (Fox et al. 1985) and the com- 
plexity of fatty acid metabolism have limited the tracer 
modeling and its clinical application. 
Also avidly extracted by the myocardium, the initial 
uptake of ~IC-acetate reflects tracer delivery and, thus, 
myocardial blood flow. Within the myocyte, 1 ~C-acetate 
is rapidly activated to acetyl-CoA, which enters the tri- 
carboxylic acid cycle. The ~1C activity equilibrates in 
the pool of tricarboxylic acid cycle intermediates (Lear 
1986) and clears in the form of ~ 1CO 2 from the myocar- 
dium as a function of the tricarboxylic acid cycle activity. 
Since the tricarboxylic cycle represents the final common 
metabolic pathway of oxidative metabolism, ~ ~ C-acetate 
can be used to assess cardiac metabolism independent 
of overall substrate utilization (Buxton et al. 1988). Sev- 
eral animal studies have demonstrated a close relation- 
ship between the ~ 1C clearance rate and myocardial oxy- 
gen consumption over a wide range of physiological con- 
ditions (Brown et al. 1987, 1989; Buxton et al. 1988). 
Comparison of ~lC-acetate clearance rate with indirect 
measures of oxygen consumption (i.e. pressure-rate 
product) has confirmed this relationship in human stu- 
dies (Armbrecht et al. 1989; Henes et al. 1989). Using 
a mono- or biexponential curve-fitting approach of PET- 
derived ~1C clearance patterns from the myocardium, 
it is possible to characterize myocardial oxidative metab- 
olism quantitatively (Armbrecht et al. 1989; Brown et al. 
1987, 1988, 1989; Buxton et al. 1988, 1989). However, 
quantitative assessment of ~lC-acetate kinetics requires 
the correction of llC_acetat e input function for z 1C me- 
tabolite contamination. Recently, Buck etal. (1991) 
demonstrated that the metabolite correction can be per- 
formed by a mathematical model. Thus, PET provides 
an non-invasive approach for the quantitative assess- 
ment of myocardial oxygen consumption. 
l SF_Deoxyglucose (lSF_FDG) traces the utilization of 
exogenous glucose by the myocardium. It competes with 
glucose for transmembranous transport and phosphory- 
lation by the hexokinase reaction to FDG-6-phosphate. 
The phosphorylated product is not further metabolized 
and does not participate in glycogen synthesis, glycolysis 
or the pentose phosphate shunt pathway (Gallagher 
et al. 1978; Phelps et al. 1979). 
18F-FDG kinetics derived from dynamic PET imag- 
ing have been successfully employed to quantify the rate 
of exogenous myocardial glucose utilization (Gambhir 
et al. 1989; Ratib etal. 1982). Although 18F-FDG is 
an analogue of glucose, its affinity for transport and 
phosphorylation differs. A function termed "lumped 
constant" corrects for this difference in the three-com- 
partmental model introduced by Sokoloff (Huang et al. 
1987; Sokoloff et al. 1977). Experimental studies have 
demonstrated the stability of this constant under various 
physiological conditions (Marshall et al. 1983a). FDG 
has been proven to provide a qualitative and quantita- 
tive evaluation of cardiac exogeneous glucose utilization. 
Clinical application of metabolic PET imaging 
The combined use of metabolic tracers and PET offers 
a unique approach to characterize non-invasively the 
metabolism of the myocardium (Fig. 3). However, an 
in-depth understanding of tracer distribution in the nor- 
mal myocardium is required to correctly assess the 
changes of tracer distribution observed in cardiac dis- 
eases. This point has become of great importance since 
recent studies have described inhomogeneous 1SF_FD G 
distribution in the normal heart. Under fasting condi- 
tions, Gropler et al. (1990) have demonstrated that 18F- 
FDG uptake was decreased in the septum as compared 
with that in the lateral wall. Using hyperinsulinaemic- 
euglycaemic clamping with and without lipid infusion, 
Hicks et al. (1991) have also reported similar inhomo- 
geneity of regional glucose metabolism, though less 
marked than under fasting conditions. As in both studies 
1 C-acetate clearance was maintained unchanged in the 
septum, decreased septal oxidative metabolism is ex- 
cluded as an explanation for this regionally decreased 
uptake of 18F-FDG. This interesting finding may reflect 
regional variability in the substrate selection. However, 
regional variation of the lumped constant or the de- 
phosphorylation rate of FDG-6-phosphate may also 
contribute to the inhomogeneity of cardiac FDG uptake. 
This hypothesis awaits further experimental evaluation. 
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Fig. 3. Positron emission tomography (PET) study of myocardial 
blood flow and glucose utilization in normal heart. Selected short 
axis (above), vertical long axis (middle) and horizontal long axis 
(below) are presented following intravenous injection of nitrogen-13 
ammonia (left panel) and lSF-FDG (right panel) 
Fig. 4. PET myocardial viability study. Reduced resting perfusion 
as determined by ~3N-ammonia (left panel) in the anterolateral 
wall with relatively increased ~SF-FDG retention (right panel) in 
the same area of this patient with prior myocardial infarction sug- 
gest the presence of ischaemically jeopardized but viable myocar- 
dinm in this territory. Short axis, above; vertical long-axis; middle, 
horizontal long axis, below 
Fig. 5. PET myocardial viability study. Reduced resting perfusion 
(left panel) with matched reduced FDG retention (right panel) in 
the inferolateral wall of this patient with prior inferior myocardial 
infarction represents non-viable myocardium in this territory 
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Assessment o f  tissue viability in stable coronary artery 
disease 
The assessment of  function, perfusion and coronary 
anatomy is an important  part  of  the evaluation of  pa- 
tients with ischaemic heart  disease. It has been well dem- 
onstrated that patients with ischaemic heart disease asso- 
ciated with left ventricular impaired function may bene- 
fit from revascularization (Alderman et al. 1983; Detre 
et al. 1981; European Coronary Surgery Study Group 
1982; Freedman etal .  1984; Passamani e ta l .  1985). 
Since improvement of  left ventricular function depends 
on the presence of  residual tissue viability, the differenti- 
ation between ischaemically compromised and non-via- 
ble myocardium has become an important  clinical ques- 
tion. Regional contractile dysfunction and reduced 
blood flow are frequently shared by infarcted and 
ischaemic tissue, complicating the identification of  viable 
tissue. Thus, the use of  metabolic tracers may represent 
a unique means to identify ischaemic myocardium with 
persistent metabolic activity which is expected to benefit 
from blood flow restoration. 
Several animal studies have demonstrated enhanced 
~SF-FDG uptake in viable, ischaemically injured myo- 
cardium (Kalff et al. 1989; Schwaiger 1986; Schwaiger 
et al. 1985). Based on these experimental data, ~SF-FDG 
has been tried in patients with coronary artery disease. 
Fig. 8. PET images following intravenous injection of rubidium-82 
(left panel) and HC-HED (right panel) in the normal heart. The 
images show a homogeneous distribution of HED throughout the 
left ventricle representing a homogeneous distribution of sympa- 
thetic nerve terminals throughout the left ventricle 
Fig. 9. PET images in a patient with recent cardiac transplantation 
Blood flow images (left panel) indicate homogeneous perfusion 
throughout the left ventricle. Images obtained following intrave- 
nous injection of 11C_HE D (right panel) show a marked reduction 
of tracer retention 
Fig. 10. PET images in a patient 55 months after cardiac transplan- 
tation. Blood flow images (left panel) show a homogeneous perfu- 
sion throughout the left ventricle. Images obtained following intra- 
venous injection of I~C-HED (right panel) show tracer retention 
in the anterobasal segment of the left ventricle which represents 
catecholamine uptake and storage in this territory 
Fig. ll .  PET images in a patient with recent myocardial infarction 
and thrombolytic therapy. Blood flow images (left panel) show 
a small perfusion abnormality in the inferolateral wall of the left 
ventricle. Images obtained following intravenous injection of ~ 1C- 
HED show a larger area with marked reduction of tracer retention, 
suggesting injury of the sympathetic nerve terminals 
Fig. 12. PET images in a patient with dilated cardiomyopathy. 
Blood flow images (left panel) show a homogeneous perfusion 
throughout the left ventricle. Images obtained following intrave- 
nous injection of 11C-HED (right panel) show a heterogeneous 
tracer retention throughout the left ventricle which represents a 
heterogeneous pattern of neuronal dysfunction 
Marshall et al. (1983 b) performed the first study involv- 
ing patients with previous myocardial infarction. They 
demonstrated a high incidence of  18F-FDG uptake in 
segments with reduced blood flow (Figs. 4, 5). Those 
myocardial segments correlated with the presence of  
postinfarction angina, the site of  ischaemic electrocar- 
diographic changes during ischaemia and the presence 
of severe coronary artery disease. This study has been 
followed by others correlating 18F-FDG uptake with 
conventional markers of  myocardial viability such as Q 
waves on the electrocardiogram (Brunken and Shelbert 
1989; Brunken et al. 1986, 1987, 1989; Tamaki e ta l .  
1988). Having demonstrated cell viability in patients 
with previous infarction, subsequent studies focused on 
the predictive value of  persistent lSF-FDG uptake in 
segments with low flow for functional recovery after re- 
vascularization. Tillisch et al. (1983) evaluated the func- 
tional recovery of  hypokinetic segments with persistent 
uptake 6 weeks after surgical revascularization. They 
demonstrated that persistent 18F-FDG uptake was 85% 
predictive for the recovery of  contractility, while the ab- 
sence of  metabolic activity in segments with low flow 
was associated with a lack of  contractile recovery. This 
observation was confirmed by others. Tamaki et al. 
(1989) showed contractility improvement in 78% of  the 
segments with persistent ~SF-FDG uptake in compari- 
son with only 22% of  the segments without it. Table 
1 summarizes the predictive value of  PET criteria for 
tissue recovery following revascularization as defined by 
the investigations of  several laboratories. 
Thallium-201 scintigraphy has been most widely ap- 
plied to detect myocardial viability in the clinical setting. 
It has been accepted that redistribution within a stress- 
induced 2o 1T1 defect represents tissue viability. However, 
more recent studies indicated that the presence of fixed 
2°1T1 defects may overestimate the scar tissue extent. 
Such investigations have shown that 30%-70% of  seg- 
ments with a fixed defect have a normalized 2°1T1 uptake 
after surgical revascularization (Gibson et al. 1983; Liu 
et al. 1985). In addition, 30%-50% of  myocardial seg- 
ments with 2o lTl_fixed defects demonstrate PET viability 
(Brunken and Schelbert 1989; Brunken et al. 1987; Ta- 
maki et al. 1988). Recently, 2°1T1 reinjection protocols 
have been introduced to improve the detection of  viable 
tissue (Dilsizian etal .  1990; Kiat etal .  1988; Ohtani 
et al. 1990). However, further comparative studies with 
PET are required to identify the benefit of this new pro- 
tocol for the detection of  viable tissue. Resting 2°~T1 
scintigraphy with delayed imaging may provide the most 
accurate definition of  tissue viability short of  PET (Rit- 
chie et al. 1979). On the other hand, PET has proven 
especially helpful at our institution in patients with se- 
verely reduced left ventricular function who were either 
considered for "' high r isk" surgical revascularization or 
heart transplantation. The excellent image quality and 
the specific metabolic information provided by PET has 
made this test an important  part  of  the clinical decision- 
making process in these patients. 
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Table 1, PET and thallium-20t SPET predictive values for recovery of contractile function following revascularization 
Technique n Viable tissue Non-viable tissue Reference 
(recovery) (no recovery) 
PET 
FDG/NH3 17 35/41(85%) 24/26(92%) Tillisch et at. 1983 
FDG/NH3 22 18/23(78%) 18/23(78%) Tamaki et al. 1989 
SPET 
Redistribution 2°~T1 24 23/3t(74%) t6/30(53%) Ohtani et al. 1990 
Reinjection Z°~T1 24 t0/14(71%) 22/26(85%) Ohtani et al. 1990 
Reinjection z°aYl 20 13/15(87%) 8/8(100%) Dilsizian et al. 1990 
Redistribution ~°aT1 21 67/73(85%) 34/112(28%) Kiat et al. 1988 
24-h redistribution 21 70/74(95 %) 30/48(63 %) Kiat et al. 1988 
FDG/NH3, Fluorine-18 fluorodeoxyglucose and nitrogen-t3 am- 
monia; SPET, single photon emission tomography; Redistribution 
a°~T|, thallium redistribution imaging at 3-4 h after stress; Reinjec- 
tion a°~T1, thallium imaging following reinjection of approximately 
I mCi of ~°~T1 3-4 h after stress; 24-h redistribution, thallium re- 
distribution imaging approximately 24 h after stress imaging 
Acute myocardial bfarction 
PET has also been used in the acute phase of myocardial 
infarction (Czernin et al. 1990; Schwaiger et al. 1986). 
Metabolic imaging has demonstrated the impairment of 
the oxidative metabolism in the clinical infarct zone 
(Walsh et al. 1989). The absence of metabolic activity 
in the infarct area has been highly predictive of complet- 
ed tissue necrosis and of no further functional recovery. 
However, persistent metabolism in the infarct territory 
revealed by 18F-FDG uptake has been associated with 
a variable functional outcome (Schwaiger et al, 1986). 
The variability of functional recovery has been interpret- 
ed as the dynamic process of cellular death after the 
ischaemic insult or subsequent vessel reocclusion. Com- 
paring coronary angiography and regional glucose me- 
tabolism, Schwaiger et at. (1987) have shown that, as 
compared with an area of infarction subtended by an 
occluded vessel, an area with persistent antegrade flow 
in the infarct vessel was characterized by enhanced ~ 8F- 
FDG uptake, confirming the beneficial effect on metab- 
olism of residual blood flow in the infarcted territory. 
All these studies were performed before the era of throm- 
bolytic therapy. It is now widely accepted that the initia- 
tion of thrombolytic therapy early after the onset of 
symptoms of myocardial infarction limits the size of the 
necrosis and improves survival (GISSI 1986; ISIS-2 
1988). Therefore, any time-consuming PET imaging may 
not be warranted before the completion of thrombolytic 
treatment. However, several reports support the notion 
that PET may play a role in the evaluation of patients 
early after the myocardial insult (Hicks et al. 1990; Van- 
overschelde et al. ]992). Due to myocardial stunning, 
it may be difficult to appreciate the success of the throm- 
bolytic treatment based on regional wall motion. In ad- 
dition, the persistence of significant stenosis in the in- 
farct vessel has been frequently reported after successful 
thrombolysis (Topol et al. 1987). Therefore, PET may 
be helpful for the early detection of the amount of sal- 
vaged as well as jeopardized viable myocardium and 
could contribute to the selection of patients who could 
benefit from revascularization in the subacute period of 
their myocardial infarction (vom Dahl et al. 1991). 
Dilated cardiomyopathy 
The pathophysiology of dilated cardiomyopathy re- 
mains poorly understood. With a few exceptions (carni- 
tine deficiency or nutritional deficiency related to alco- 
hol consumption), there is no evidence that a metabolic 
abnormality is directly associated with this cardiac dis- 
ease. So, contrary to ischaemic heart disease, we cannot 
rely on experimental data to guide metabolic imaging 
approaches for the diagnosis and staging of the myo- 
pathic process. Therefore, metabolic imaging only indi- 
rectly reflects the deterioration of overall left ventricular 
performance. 
Without history or electrocardiographic signs of pre- 
vious myocardial infarction, it may be difficult to differ- 
entiate ischaemic and non-ischaemic cardiomyopathy. 
Using PET with 13NH3 and 18F-FDG, Mody-Vaghaiw- 
alla et al. (1988) demonstrated the accuracy of cardiac 
imaging to differentiate ischaemic heart disease and idio- 
pathic dilated cardiomyopathy. 13NH3 and aSF-FDG 
patterns were more homogeneous in patients with 
ischaemic than non-ischaemic cardiomyopathy. Gelt- 
man et al. (1983) also described similar distinct patterns 
of 1 ~C-palmitate distribution between patients with pre- 
vious myocardial infarction and those with non- 
ischaemic cardiomyopathy. 
Employing analysis of the l~C-palmitate kinetics, 
Schelbert et al. (1986) studied the free fatty acid metabo- 
lism in patients with severely impaired ventricular func- 
tion. Following glucose oral loading, they showed that 
more than 40% of these patients had a paradoxical acce- 
lerated clearance of 1 ~C-palmitate activity as compared 
with normals. The biochemical mechanism and the sig- 
nificance of this observation remain unclear and require 
further clinical investigations. More recently, the cardiac 
oxidative metabolism of patients with dilated cardio- 
myopathy has been assessed using ~aC-acetate (Chan 
et al. 1990). Following correction for the loading condi- 
tions of the left ventricle, the oxygen consumption was 
found to be decreased in these patients. Experimental 
data in the canine model suggest that the cardiac perfor- 
mance of the impaired left ventricle may be non-invas- 
ively assessed by a combined use of a~C-acetate clear- 
ance and echocardiographically derived parameters of 
cardiac work efficiency (Wolpers et al. 1990). Such a 
measurement of myocardial efficiency may allow a non- 
invasive determination of therapeutic interventions by 
serial metabolic and echocardiographic studies. 
B, Evaluation of cardiac innervation 
The heart is characterized by its ability to respond quick- 
ly to changing body demands. This integrated function 
is achieved through the autonomic nervous system. Both 
sympathetic and parasympathetic nervous systems in- 
nervate the heart and regulate cardiac electrophysiologi- 
cal and hemodynamic adaptation to varying demands. 
The neurotransmitters of the sympathetic and parasym- 
pathetic nervous systems are noradrenaline and acetyl- 
choline, respectively. The atria, the sinoatrial node and 
the atrioventricular node are regulated by both the sym- 
pathetic and parasympathetic nervous systems. How- 
ever, the neuronal structure in the ventricular myocar- 
dium are primarily sympathetic nerve fibres. Based on 
the measurement of the tissue noradrenaline content, 
the heart displays a denser sympathetic fibre network 
in the right than in the left ventricle as well as in the 
base than in the apex of the ventricles (Angelakos 1965; 
Angelakos et al. 1969; Pierpont et al. 1985). Histology 
as well as electrophysiology studies suggest that the sym- 
pathetic nerves travel in the superficial subepicardium 
of the ventricles primarily following the coronary vessels 
(Randall and Ardell 1988). As they progress from base 
to apex, they gradually penetrate the myocardium and 
innervate the endocardium by plexus terminals. The 
sympathetic nerve terminals include vesicles which repre- 
sent a storage pool for the neurotransmitter, enzymes 
and other proteins (Fig. 6). Upon nerve stimulation, nor- 
adrenaline is released by exocytosis in the synaptic cleft. 
The regulation of the adrenaline release is complex and 
is mediated by different presynaptic receptors (Francis 
1988; Muscholl et al. 1979). Noradrenaline itself exerts 
a negative feed-back control by fixation on ea presynapt- 
ic receptors (Langer 1980). The fate of the released nor- 
adrenaline is manifold. Only a small amount activates 
specific receptors on the surface of the myocytes, and 
a fraction present in the synaptic cleft diffuses in to the 
vascular space. The majority of the extraneuronal nor- 
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Fig. 6. Sympathetic nerve terminal and noradrenaline metabolism: 
NE, norepinephrine; TYR, tyrosine; DHPG, dihydroxyphenolgly- 
col; DBH, dopamine fl-hydroxylase; MAO, monoamine oxidase 
adrenaline is removed by the nerve terminal itself (Gold- 
stein et al. 1988). This reuptake, called uptake-l, re- 
moves as much as 70% of the released noradrenaline 
and plays an important role in the regulation of the 
extraneuronal noradrenaline tissue concentrations (Ax- 
elrod 1960). Following reuptake into the nerve terminal, 
noradrenaline is concentrated again in the storage vesi- 
cles for subsequent release (Njus et al. 1986). Noradrena- 
line is metabolized by monoamine oxidase (MAO) in 
the neuronal cytosol and by catechol-O-methyl transfer- 
ase (COMT) principally concentrated in non-neuronal 
tissue. 
Contrary to the sympathetic nervous fibres, the 
sparse parasympathetic fibres travel along the ventricles 
in the subendocardium and subsequently penetrate up- 
ward to innervate the epicardium (Zipes and Inoue 
1988). Acetylcholine, the parasympathetic neurotrans- 
mitter, is synthesized by the acetylation of choline. Cho- 
line enters the cytosol of the nerve terminals via the 
high-affinity choline uptake system (Ducis 1988) and is 
rapidly acetylated by choline acetyltransferase. Then 
acetylcholine is shuttled into the storage vesicles. The 
vesicular uptake system also presents a high specific af- 
finity for acetylcholine (Zimmermann 1988). Upon nerve 
stimulation, acetylcholine is released, activates postsyn- 
aptic receptors and is rapidly hydrolyzed by the great 
quantities of acetylcholinesterase. 
PET radiopharmaceuticals 
for mapping presynaptic nerve terminals 
Sympathetic  neuron tracers 
18F-metaraminol (FMR) (Mislankar et al. 1988) and 
11C-hydroxyephedrine (HED) (Rosenpire et al. 1990) 
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amine analogues, 6JSF-fluorometaraminol (FMR) and 11C-meta- 
hydroxyephedrine (HED) 
have been developed to characterize non-invasively the 
sympathetic nerve terminals of the heart using PET im- 
aging (Fig. 7). FMR, a false neurotransmitter which is 
a close structural analogue of noradrenaline, has been 
chosen for its high affinity for uptake-1. As compared 
with noradrenaline, FMR is characterized by the pres- 
ence of an e-methyl group and the absence of a catechol 
group. This particular chemical structure protects FMR 
against metabolization by monoamine oxidase (MAO). 
Once in the neuronal cytoplasm, FMR is sequestered 
in the storage vesicles and, upon stimulation, is released 
with endogenous noradrenaline. However, the specific 
activity achievable by labelling metaraminol with fluor- 
ine-18 has been low. The mass of unlabelled FMR in 
projected clinical doses has been, thus, too close to phar- 
macological levels for safe use in humans. ~aC-HED, 
very similar to FMR, has been chosen as an alternate 
radiopharmaceutical for use in human studies and has 
been labelled with high specific activity. To verify the 
specificity of FMR (Wieland et al. 1990) and HED (Wie- 
land et al., unpublished data) retention by sympathetic 
nerve terminals, the tracers have been injected into ani- 
mals after pretreatment by desipramine (uptake-1 inhibi- 
tor) or reserpine (vesicle storage inhibitor). As compared 
with controls, desipramine as well as reserpine have dra- 
matically decreased the tissue tracer retention. These 
data indicate that the tracer retention specifically reflects 
neuronal uptake and vesicular storage. 
PET imaging techniques have been employed to eval- 
uate both radiopharmaceuticals for non-invasive assess- 
ment of the distribution of sympathetic nerve terminals. 
Tracer kinetics have been studied in a chronic dog model 
with regional denervation of the heart through the epi- 
cardial application of phenol. Both the FMR and HED 
tissue concentrations as assessed by PET have been 
found to correlate linearly with the regional noradrena- 
line content of the myocardium (Wieland et al. 1990). 
Parasympathet ic  neuron tracers 
The synthesis of tracers for the parasympathetic neuron 
remains difficult. They must have a chemical structure 
that not only resists hydroxylation by acetylcholinester- 
ase but also is recognized by the high specific transport 
and storage systems. Vesamicol (an analgesic compound) 
and its benzo-derivatives display a high affinity for the 
parasympathetic synaptic vesicles and may represent val- 
uable tracers (Brittain et al. 1969; Rogers et al. 1989). 
However, further studies are needed to confirm the spec- 
ificity of their retention in parasympathetic nerve termi- 
nals. 
PET agents for mapping postsynaptic receptors 
The l~C-labelled /~-blockers were synthesized to trace 
the/Lreceptor distribution of the heart but have found 
limited use in PET imaging because of intense pulmo- 
nary uptake due to their lipophilicity. Early results with 
the hydrophilic compound ~1C-CGP12177 are promis- 
ing for the in vivo evaluation of myocardial/Lreceptors 
in animal (Delforge et al. 1991b) and human studies 
(Merlet et al. 1991). 
*lCN-methyl quinuclinidyl benzilate Q~C-methyl- 
QNB) (Delforge et al. 1991a; Maziere et al. 1981) and 
a lCN-methyl tropapyl benzilate (~aC-methyl-TRB) 
(Mulholland et al. 1988) represent potential tracers to 
delineate the muscarinic receptor distribution of the hu- 
man heart. Animal and clinical studies have shown a 
high tracer uptake in the heart with little non-specific 
binding (Brown and Golstein 1986; Fields et al. 1978; 
Mulholland et al. 1989; Syrota et al. 1985). 
Clinical evaluation 
of sympathetic nerve terminals 
PET investigations of the human sympathetic nervous 
system at our institution have been limited to the use 
of 11C_HED. After 1 ~C-HED administration, high qual- 
ity images of the heart can be achieved (Schwaiger et al. 
1990). The distribution of laC-HED is homogeneous 
throughout the normal heart, reflecting the distribution 
of sympathetic fibres throughout the myocardium 
(Fig. 8). The study of patients soon after heart transplan- 
tation provided a unique model of cardiac denervation 
(Schwaiger et al. 1991). The I~C-HED myocardial con- 
tent was homogeneous in these patients, but the tracer 
retention in the transplanted heart was reduced by 76% 
in comparison with the normal heart. These results con- 
firmed the specificity of the tracer for neuronal struc- 
tures. 
Reinnervation of transplanted organs has been dem- 
onstrated in animals, but reinnervation of the human 
heart transplant has remained controversial. The study 
of patients with a remote heart transplantation (3.5 _+ 1.3 
461 
years) demonstrated an inhomogeneous pattern of 11C_ 
H E D cardiac retention. Higher tracer uptake in the basal 
region of  the left ventricle was observed, providing the 
first direct evidence of  cardiac reinnervation after trans- 
plantation in humans (Figs. 9, 10). The pattern of  11C- 
H E D uptake suggests partial reinnervation along the 
anterior surface of  the heart. Correlation with functional 
measures of  the autonomic nervous system are needed 
to define the clinical significance of  these scintigraphic 
findings. 
Combined studies of  perfusion and neuronal function 
using 11C-HED in patients with acute myocardial infarc- 
tion have revealed a neuronal dysfunction of  the 
ischaemically injured myocardium, confirming previous 
animal studies (Allman et al. 1991) (Fig. 11). Since the 
heterogeneity of  sympathetic tone has been linked to 
dysrhythmia in patients with ischaemic heart disease, 
this imaging approach may provide information which 
may help to identify patients with a high risk for sudden 
death. 
Abnormality of the sympathetic nervous system has 
also been described in patients with dilated cardiomyo- 
pathy. In these patients, an increase of the sympathetic 
tone involving high plasma noradrenaline levels reflects 
a physiological response to a decreased cardiac output. 
In vitro studies have demonstrated a decrease of  the 
postsynaptic/?-receptor density in patients with conges- 
tive heart failure which has been interpreted as/?-recep- 
tor down-regulation resulting from noradrenaline over- 
stimulation (Bristow etal .  1982; Fowler etal .  1986; 
Francis and Cohn 1986). Since the reuptake and storage 
of noradrenaline in the presynaptic nerve terminals is 
an important  mechanism for regulating the extraneuron- 
al noradrenaline content, the dysfunction of  the nerve 
terminals may be an important  pathophysiological 
mechanism in catecholamine overexposure of  the post- 
synaptic receptor sites. Scintigraphy studies with sIC- 
H ED in patients with failing hearts have shown a de- 
crease of tracer retention in comparison with normal 
control patients (Schwaiger et al. 1990). The degree of  
abnormality varied regionally, indicating a heteroge- 
neous pattern of  neuronal dysfunction (Fig. 12). These 
PET data indicate an altered neuronal reuptake function 
in cardiomyopathy and, thus, support  the notion of/?- 
receptor down-regulation due to presynaptic dysfunc- 
tion. This hypothesis is strengthened by recent clinical 
observations reporting beneficial effects of  /?-receptor 
blockade in patients with congestive heart failure (Waag- 
stein et al. 1989). Thus, quantitative delineation of  the 
sympathetic function by PET may aid in the selection 
of  patients for therapy with/?-receptor blockers and con- 
tribute to the better understanding of  the abnormalities 
of  sympathetic innervation in dilated cardiomyopathy. 
Conclusion 
PET provides a unique scientific tool to probe non-inva- 
sively the biochemistry and other tissue functions of  the 
living heart. The current progress in both PET technolo- 
gy and tracer kinetics modelling now allow quantitative 
evaluation of  regional physiologic processes such as 
blood flow, metabolic rates and neuronal function. In 
severe coronary artery disease, metabolic imaging with 
PET has proven to be clinically useful for the definition 
of  tissue viability. This application represents the most 
commonly employed PET study in cardiac patients at 
our institution. In non-ischaemic heart disease, PET 
must still be considered experimental and requires fur- 
ther clinical validation. The recent development of  neu- 
ronal tracers presents an opportunity to image the auto- 
nomic nervous system of  the heart. The availability of  
short-lived radiopharmaceuticals allows the character- 
ization of  different aspects of  neuronal function, such 
as presynaptic and postsynaptic tracer binding. The un- 
ique information provided by PET in neurocardiology 
will make this technique an attractive research tool for 
the delineation of  neuronal abnormalities in various car- 
diovascular disease processes. However, at the present 
time, there are no clearly defined clinical applications 
of  neuroimaging in cardiac patients. 
We are confident that future PET research studies 
employing sophisticated, mathematical tracer modelling 
and the synthesis of  new radiopharmaceuticals will con- 
tribute to a better understanding of cardiac metabolism 
and regulation of  cardiac function by the autonomic ner- 
vous system. 
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